INNO-LiPA HBV DR v2
INNO-LiPA HBV DR v2 is a line probe assay for the simultaneous detection of hepatitis B virus wild-type and drug-induced mutations associated with adefovir and lamivudine drug resistance, including all currently known clinically relevant mutations as well as known compensatory mutations.
Article number: 80349 (20T - CE)
Innovative, standardized, and sensitive tool for detection of HBV drug resistance mutations
Features & Benefits
Multiple results
-
Allows simultaneous detection of HBV polymerase wild-type and drug-induced mutations associated with adefovir and lamivudine resistance as well as known compensatory mutations (codons 80, 173, 180, 181, and 204)
-
Identifies amino acid changes in the overlapping reading frame of HBsAg (codons 171, 172, 195, 196, 198, and 199)
-
Optimized for 8 known HBV genotypes (A-H)
Sensitivity
-
Correctly reflects the complex quasispecies nature of HBV, as demonstrated by clonal analysis of follow-up samples
-
Provides highly sensitive detection at single nucleotide level of mixtures of wild-type and mutants, identifying the appearance of mutants earlier than sequencing and viral load assays
-
Helps unravel the dynamics of emerging HBV resistance
Strip design
Click
INNO-LiPA HBV DRv2 to view the commercial leaflet.
Click
INNO-LiPA HBV Clinician to view the clinical leaflet.
Click
INNO-LiPA HBV Technical to view the technical leaflet.
Relevant scientific articles
-
Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, et al.Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38:702-7.
-
Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-88.
-
Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus trains in patients under various clinical conditions. J Clin Microbiol 2001;39:1972-4.
-
Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-91.
-
Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002;36:303-4.
-
Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002;40:3729-34.
-
Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, Lok AS. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol. 2006 Mar;44(3):1094-7.
Related products
INNO-LiPA HBV PreCore
INNO-LiPA HBV Genotyping
Customer support
For all inquiries regarding Innogenetics products and instrumentation, we offer the services of our customer support team. This team of technical experts is committed to dealing with
-
General inquiries
-
Technical assistance
-
Complaint resolution
The customer support team is designed to be your principle point of contact. They will ensure that the appropriate person handles all product-related inquiries. For this service please contact us via e-mail, call us (+32-9 329 16 11), or fax (+32-9 329 17 75).